벡터 정제 시장 : 업계 동향과 세계 예측 - 바이러스 벡터 유형별, 정제 기술 유형별, 치료 유형별, 치료 영역별, 사업 규모별, 주요 지역별

Vector Purification Market: Industry Trends and Global Forecasts - Distribution by Type Of Viral Vector, Type of Purification Technique, Type Of Therapy, Therapeutic Area, Scale of Operation and Key Geographical Regions

US $ 4,799 ￦ 6,650,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,999 ￦ 9,699,000

PDF (One-Location Site License)

PDF 보고서를 동일 사업장의 특정 사업 부문에 속한 모든 분들이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,599 ￦ 14,688,000

PDF (Department License)

PDF 보고서를 부서 단위로 12명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 17,999 ￦ 24,943,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

벡터 정제 시장 : 개요

세계의 벡터 정제 시장 규모는 올해 1억 5,500만 달러에 달했습니다. 이 시장은 예측 기간 중 21%의 유리한 CAGR로 성장할 것으로 예측됩니다.

시장 세분화 및 기회 분석은 다음과 같은 매개 변수로 세분화됩니다.

바이러스 벡터 유형

• AAV
• 아데노바이러스
• 렌치 바이러스
• 레트로 바이러스
• 기타

정제 기술 유형

• 크로마토그래피
• 원심분리
• 여과

치료 유형

• 유전자 치료
• 세포치료
• 바이러스 백신

치료 영역

• 종양학 질환
• 심혈관 질환
• 안과 질환
• 대사성 질환
• 염증-면역질환
• 기타

사업 규모

• 전임상/임상
• 상업

주요 지역

• 북미
• 유럽
• 아시아태평양
• 기타 지역

벡터 정제 시장 : 성장과 동향

바이러스 벡터는 유전물질을 표적 세포로 운반하는 데 사용되는 생물학적 툴입니다. 복잡하고 자원 집약적인 과정임에도 불구하고 세포-유전자 치료제의 개발 및 제조는 큰 추진력을 보이고 있으며, 후기 임상시험 및 시장 승인을 향해 나아가는 임상 프로그램도 증가하고 있습니다. 현재 시판 중인 세포-유전자 치료제는 30개 이상이며, 수백 건의 혁신적인 치료법에 대한 임상시험이 진행 중입니다. 또한 COVID-19 팬데믹으로 인해 현재 임상시험에 개입 중인 치료법의 수가 눈에 띄게 증가하고 있습니다. 그러나 현재 바이러스 벡터의 정제 방법에는 많은 공정이 있고, 제품 손실이 크고 수율이 낮은 것으로 알려져 있습니다.

바이러스 벡터에 대한 수요 증가와 다운스트림 정제에 대한 확장성 부족 및 기타 우려로 인해 이 분야의 이해관계자들은 바이러스 정제를 위한 새롭고 효과적인 솔루션을 개발하기 위해 다양한 노력을 기울이고 있습니다. 최근 이해관계자들은 친연성 크로마토그래피 기반의 바이러스 정제 요법에 대한 의존도를 높이기 시작했습니다. 또한 필터 플레이트, 사전 포장된 크로마토그래피 컬럼 및 수지, 연결 키트 등 벡터 정제를 위한 다양하고 혁신적인 솔루션을 제공한다고 주장하는 기업도 있습니다.

벡터 정제 시장 : 주요 인사이트

이 보고서는 세계 벡터 정제 시장의 현황을 파악하고 업계내 잠재적인 성장 기회를 파악합니다. 이 보고서의 주요 조사 결과는 다음과 같습니다.

• 바이러스의 회수율을 높이고 오염물질과 불순물을 효과적으로 제거하기 위해 다양한 다운스트림 처리 기술을 이용한 100가지 이상의 바이러스 벡터 정제 제품이 개발되고 있습니다.
• 사용 가능한 대부분의 바이러스 정제 제품은 소규모/임상 규모에서 사용하도록 설계되었으며, 벡터 유형에 따른 특정 요구 사항을 충족하도록 설계되었습니다.
• 현재의 위기 상황에서 바이러스 벡터 기반 백신의 연구개발이 급증함에 따라 대규모 바이러스 정제 솔루션에 대한 수요가 증가할 것으로 예측됩니다.
• 아데노바이러스 벡터는 세포치료 및 유전자치료에 널리 사용되므로 여러 업체에서 이러한 바이러스용 키트, 수지, 컬럼 등의 제품을 제공합니다.
• Bio-Rad Laboratories, Cytiva, Thermo Fisher Scientific 등은 북미에 기반을 둔 주요 기업입니다.
• 수년 동안 다양한 질병에 대한 다양한 바이러스 벡터 기반 치료법과 백신을 평가하는 1,000개 이상의 임상시험이 등록되어 세계 각지에서 진행되고 있습니다.

• 기존 바이러스 정제 공정을 강화하고 최적화하기 위해 일부 바이러스 벡터 의약품 개발 및 제조 기업은 정제 제품 개발 기업과 제휴할 가능성이 높습니다.
• 전 세계 35개 이상의 기업이 자체적으로 또는 위탁 생산의 일환으로 다양한 유형의 바이러스 벡터를 상업적 규모로 생산할 수 있는 역량을 보유하고 있습니다.
• 바이러스 세포 치료 및 유전자 치료에 초점을 맞춘 R&D 구상이 증가함에 따라 다양한 치료 적응증에서 다양한 유형의 바이러스 벡터에 대한 임상 및 상업적 수요가 증가할 것으로 예측됩니다.
• 승인된 유전자 재조합 치료제가 많지 않기 때문에 현재 수요는 바이러스 벡터 기반 치료제에 대한 다양한 임상시험에 등록한 환자들에 의해 주도되고 있습니다.
• 현재 상업적 수요의 40% 이상이 아데노바이러스에 기인하고 있는데, 이는 시판 중인 치료법에 널리 사용되고 있기 때문입니다. 또한 렌티 바이러스는 임상 수요의 약 35%에 기여하고 있습니다.
• 또한 렌치바이러스는 임상 수요의 약 35%에 기여하고 있습니다. 대부분의 바이러스 벡터는 종양성 질환을 앓고 있는 환자를 위해 개발되고 있지만, 향후 수년간은 신경질환과 근육질환이 큰 수요를 창출할 것으로 보입니다.
• 시장은 예측 기간 중 CAGR 21% 이상 성장할 것으로 예상되며, 기회는 다양한 유형의 정제 기술, 바이러스 벡터, 주요 지역에 걸쳐 분포할 것으로 보입니다.

벡터 정제 시장의 참여 기업 예

• Agilent Technologies
• BIA Separations
• Bio-Rad Laboratories
• BioVision
• Cytiva(formerly GE Lifesciences)
• Merck
• Sartorius
• Takara Bio
• Thermo Fisher Scientific

목차

제1장 서문

제2장 개요

제3장 서론

• 챕터 개요
• 바이러스성 및 비바이러스성 유전자 도입법
• 유전자변형 치료용 바이러스 벡터
• 바이러스 벡터 유형
• 바이러스 벡터의 응용
• 벡터 개발·제조의 최신 동향
• 벡터 제조
• 벡터 정제의 미래

제4장 시장 구도

• 챕터 개요
• 바이러스 벡터 정제 제품 : 시장 구도
• 바이러스 벡터 정제 제품 개발자

제5장 기업 개요

• 챕터 개요
• Agilent Technologies
• BIA Separations
• Bio-Rad Laboratories
• BioVision
• Cytiva(formerly GE Lifesciences)
• Merck
• Sartorius
• Takara Bio
• Thermo Fisher Scientific

제6장 전략적 파트너 분석

• 챕터 개요
• 조사 방법과 주요 파라미터
• 잠재적 전략적 파트너 : 바이러스 벡터 기반 치료법 개발자
• 잠재적 전략적 파트너 : 바이러스 벡터 제조업체

제7장 임상시험 분석

• 챕터 개요
• 범위와 조사 방법
• 바이러스 벡터를 이용한 치료법 : 임상시험 분석
• AAV 벡터 기반을 이용한 치료법
• 아데노바이러스 벡터를 이용한 치료법
• 렌티바이러스 벡터를 이용한 치료법
• 레트로바이러스 벡터를 이용한 치료법
• 기타 바이러스 벡터를 이용한 치료법

제8장 수요 분석

• 챕터 개요
• 전제와 조사 방법
• 바이러스 벡터에 대한 세계의 임상 수요
• 바이러스 벡터에 대한 세계의 상업 수요

제9장 사례 연구 : 접선유동여과(TFF)

제10장 사례 연구 : 바이러스 벡터 제조업체

제11장 시장 규모의 평가와 기회 분석

• 챕터 개요
• 예측 조사 방법과 주요 전제조건
• 바이러스 벡터 정제 제품 시장 전체(-2035년)
• AAV 벡터용 바이러스 벡터 정제 제품 시장(-2035년)
• 아데노바이러스 벡터용 바이러스 벡터 정제 제품 시장(-2035년)
• 렌티바이러스 벡터용 바이러스 벡터 정제 제품 시장(-2035년)
• 레트로바이러스 벡터용 바이러스 벡터 정제 제품 시장(-2035년)
• 기타 바이러스 벡터용 바이러스 벡터 정제 제품 시장(-2035년)

제12장 결론

제13장 이그제큐티브 인사이트

제14장 부록 1 : 표형식 데이터

제15장 부록 2 : 기업·단체 리스트

KSA

영문 목차

영문목차

VECTOR PURIFICATION MARKET: OVERVIEW

As per Roots Analysis, the global vector purification market valued at USD 155 million in the current year is anticipated to grow at a lucrative CAGR of 21% during the forecast period.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Viral Vector

• AAV
• Adenovirus
• Lentivirus
• Retrovirus
• Others

Type of Purification Technique

• Chromatography
• Centrifugation
• Filtration

Type of Therapy

• Gene Therapy
• Cell Therapy
• Viral Vaccines

Therapeutic Area

• Oncological Disorders
• Cardiovascular Disorders
• Ophthalmic Disorders
• Metabolic Disorders
• Inflammation & Immunological Diseases
• Others

Scale of Operation

• Preclinical / Clinical
• Commercial

Key Geographical Regions

• North America
• Europe
• Asia- Pacific
• Rest of the World

VECTOR PURIFICATION MARKET: GROWTH AND TRENDS

Viral vectors are the biological tools that are used to transport genetic material to the target cell. Despite being a complex and resource-intensive process, development and manufacturing of cell and gene therapies has gained substantial momentum, with an increasing number of clinical programs moving to later-phase clinical trials and towards market approval. There are currently over 30 commercially available cell and gene therapy products, along with hundreds of ongoing clinical trials for these innovative therapies. Further, the COVID-19 pandemic has led to a notable rise in the number of therapies that are currently under intervention in clinical trials. However, the current purification methods for viral vectors involve a multitude of steps, which are known to be associated with high product losses and lower yields.

Gradually, rising demand for viral vectors coupled with lack of scalability and other concerns related to downstream purification, have led stakeholders in this domain to undertake various initiatives to develop novel and effective solution for virus purification. Recently, stakeholders have begun relying more on affinity chromatography-based virus purification regimens. Further, there are several companies that claim to offer a diverse range of innovative solutions for vector purification, including filter plates, prepacked chromatography columns and resins, and consolidated kits.

VECTOR PURIFICATION MARKET: KEY INSIGHTS

The report delves into the current state of the global vector purification market and identifies potential growth opportunities within industry. Some key findings from the report include:

• Over 100 viral vector purification products, involving the use of a variety of downstream processing techniques, have been developed to improve virus recovery and facilitate effective removal of contaminants / impurities.
• Most of the available virus purification products have been designed for small / clinical scale use, catering to specific requirements of different types of vectors; North America emerged as the hub of development of such solutions.
• Given the surge in R&D on viral vector-based vaccines in the current crisis, the demand for large scale virus purification solutions is anticipated to be on the rise.
• Adenoviral vectors are widely used in cell and gene therapies; hence, several players offer products, such as kits, resins and columns, for such viruses.
• Majority of developers are based in North America; Bio-Rad Laboratories, Cytiva and Thermo Fisher Scientific are some of the large players based in the region.
• Over the years, more than 1,000 clinical trials, evaluating various viral vector-based therapies and vaccines, across a wide range of diseases, have been registered and are being conducted in different global regions.

• In order to augment and further optimize existing virus purification processes, several viral vector drug developers and manufacturers are likely to forge alliances with purification product developers.
• Over 35 players across the globe are capable of manufacturing different types of viral vectors at commercial scale, either for in-house requirements or as part of contract manufacturing engagements.
• Owing to the rise in R&D initiatives focused on viral cell and gene therapies, the clinical and commercial demand for various types of viral vectors is expected to increase, across a variety of therapeutic indications.
• Since only a few genetically modified therapies have been approved, the current demand is being driven by the patients enrolled in various clinical trials for viral vector-based therapies.
• Currently, over 40% of commercial demand is attributed to adenoviruses due to their wide use in marketed therapies; further, lentiviruses contribute to about 35% of the clinical demand.
• Majority of viral vectors are being developed for patients suffering from oncological disorders; in the coming years, neurological disorders and muscular disorders, are likely to generate a significant demand.
• The market is anticipated to grow at a CAGR of over 21% during the forecast period, and the opportunity is likely to be distributed across different types of purification techniques, viral vectors and key geographical regions.

Example Players in the Vector Purification Market

• Agilent Technologies
• BIA Separations
• Bio-Rad Laboratories
• BioVision
• Cytiva (formerly GE Lifesciences)
• Merck
• Sartorius
• Takara Bio
• Thermo Fisher Scientific

VECTOR PURIFICATION MARKET: RESEARCH COVERAGE

• Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the vector purification market, focusing on key market segments, including [A] type of viral vector, [B] type of purification technique, [C] type of therapy, [D] therapeutic area, [E] scale of operation and [F] key geographical regions.
• Market Landscape: A comprehensive evaluation of companies providing products for purification of viruses / viral vectors, based on several relevant parameters, such as [A] type of product, [B] type of purification technique, [C] scale of operation, [D] type of viral vector and [E] details on other physical and operational parameters of the product. Additionally, a comprehensive evaluation of purification product developers, based on parameters, such as [A] the year of establishment, [B] company size and [C] location of headquarters.
• Company Profiles: In-depth profiles of the players engaged in this domain, focusing on [A] overview of the company, [B] product portfolio and [C] recent developments and an informed future outlook.
• Strategic Partner Analysis: A detailed analysis of the potential strategic partners for viral vector purification product developers, based on various parameters, such as [A] type of viral vector, [B] developer strength, [C] operational strength, [D] therapeutic area, [E] strength of clinical pipeline and [F] strength of preclinical pipeline.
• Clinical Trial Analysis: An in-depth analysis of clinical studies of different viral-vector based therapies, examining factors, such as [A] registration year, [B] phase of development, [C] trial status, [D] type of therapy, [E] therapeutic area, [F] type of sponsor / collaborator, [G] geographical location, [H] number of patients enrolled and [I] key players.
• Demand Analysis: A detailed analysis of the current and future demand for viral vectors, based on various parameters, such as [A] target patient population, [B] dosing frequency, [C] dose strength, [E] type of viral vector, [F] type of therapy, [G] therapeutic are and [h] geographical location.
• Case Study 1: A detailed discussion on tangential flow filtration (TFF), representing the role, advantages and disadvantages of the various techniques used for purification of viral vectors; featuring the details of products used for TFF, including [A] product type, [B] scale of operation, [C] membrane material, [D] flow rate and [E] filtration area.
• Case Study 2: Elaborate assessment of viral vector manufacturers providing commercial scale production, focusing on details, such as [A] year of establishment, [B] company size, [C] type of viral vector, [D] purpose of production, [E] location of headquarters and [F] manufacturing facilities.

KEY QUESTIONS ANSWERED IN THIS REPORT

• How many companies are currently engaged in this market?
• Which are the leading companies in this market?
• What factors are likely to influence the evolution of this market?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

• Complimentary PPT Insights Packs
• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 15% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

• 1.1. Scope of the Report
• 1.2. Research Methodology
  • 1.2.1. Research Assumptions
  • 1.2.2. Project Methodology
  • 1.2.3. Forecast Methodology
  • 1.2.4. Robust Quality Control
  • 1.2.5. Key Considerations
    • 1.2.5.1. Demographics
    • 1.2.5.2. Economic Factors
    • 1.2.5.3. Government Regulations
    • 1.2.5.4. Supply Chain
    • 1.2.5.5. COVID Impact / Related Factors
    • 1.2.5.6. Market Access
    • 1.2.5.7. Healthcare Policies
    • 1.2.5.8. Industry Consolidation
• 1.3 Key Questions Answered
• 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

• 3.1. Chapter Overview
• 3.2. Viral and Non-Viral Methods of Gene Transfer
• 3.3. Viral Vectors for Genetically Modified Therapies
• 3.4. Types of Viral Vectors
  • 3.4.1. Adeno-associated Viral Vectors
  • 3.4.2. Adenoviral Vectors
  • 3.4.3. Lentiviral Vectors
  • 3.4.4. Retroviral Vectors
  • 3.4.5. Other Viral Vectors
    • 3.4.5.1. Alphavirus
    • 3.4.5.2. Foamy Virus
    • 3.4.5.3. Herpes Simplex Virus
    • 3.4.5.4. Sendai Virus
    • 3.4.5.5. Simian Virus
    • 3.4.5.6. Vaccinia Virus
• 3.6. Applications of Viral Vectors
  • 3.6.1. Cell and Gene Therapy
  • 3.6.2. Vaccinology
• 3.7. Current Trends in Vector Development / Manufacturing
  • 3.7.1. Vector Engineering
  • 3.7.2. Cargo Engineering
• 3.8. Vector Manufacturing
  • 3.8.1. Types of Vector Manufacturers
  • 3.8.2. Viral Vector Manufacturing Process
  • 3.8.3. Challenges Related to Vector Manufacturing
    • 3.8.3.1. Vector Purification Process
    • 3.8.3.2. Techniques Used for Vector Purification
      • 3.8.3.2.1. Centrifugation and Ultra-Centrifugation
      • 3.8.3.2.2. Filtration
      • 3.8.3.2.3. Chromatography
    • 3.8.3.3. Challenges Related to Vector Purification
• 3.9. Future of Vector Purification

4. MARKET LANDSCAPE

• 4.1. Chapter Overview
• 4.2. Viral Vector Purification Products: Overall Market Landscape
  • 4.2.1. Analysis by Type of Product
  • 4.2.2. Analysis by Type of Purification Technique
  • 4.2.3. Analysis by Scale of Operation
  • 4.2.4. Analysis by Type of Viral Vector
  • 4.2.5. Viral Vector Purification Products for Chromatography
    • 4.2.5.1. Analysis by Type of Chromatographic Technique
  • 4.2.6. Viral Vector Purification Products for Centrifugation
  • 4.2.7. Viral Vector Purification Products for Filtration
• 4.3. Viral Vector Purification Product Developers
  • 4.3.1. Analysis by Year of Establishment
  • 4.3.2. Analysis by Company Size
  • 4.3.3. Analysis by Geographical Location

5. COMPANY PROFILES

• 5.1. Chapter Overview
• 5.2. Agilent Technologies
  • 5.2.1. Company Overview
  • 5.2.2. Product Portfolio
  • 5.2.3. Recent Developments and Future Outlook
• 5.3. BIA Separations
  • 5.3.1. Company Overview
  • 5.3.2. Product Portfolio
  • 5.3.3. Recent Developments and Future Outlook
• 5.4. Bio-Rad Laboratories
  • 5.4.1. Company Overview
  • 5.4.2. Product Portfolio
  • 5.4.3. Recent Developments and Future Outlook
• 5.5. BioVision
  • 5.5.1. Company Overview
  • 5.5.2. Product Portfolio
  • 5.5.3. Recent Developments and Future Outlook
• 5.6. Cytiva (formerly GE Lifesciences)
  • 5.6.1. Company Overview
  • 5.6.2. Product Portfolio
  • 5.6.3. Recent Developments and Future Outlook
• 5.7. Merck
  • 5.7.1. Company Overview
  • 5.7.2. Product Portfolio
  • 5.7.3. Recent Developments and Future Outlook
• 5.8. Sartorius
  • 5.8.1. Company Overview
  • 5.8.2. Product Portfolio
  • 5.8.3. Recent Developments and Future Outlook
• 5.9. Takara Bio
  • 5.9.1. Company Overview
  • 5.9.2. Product Portfolio
  • 5.9.3. Recent Developments and Future Outlook
• 5.10. Thermo Fisher Scientific
  • 5.10.1. Company Overview
  • 5.10.2. Product Portfolio
  • 5.10.3. Recent Developments and Future Outlook

6. STRATEGIC PARTNER ANALYSIS

• 6.1. Chapter Overview
• 6.2. Methodology and Key Parameters
• 6.3. Potential Strategic Partners: Viral Vector-based Therapy Developers
  • 6.3.1. Strategic Partner Analysis: AAV Vector-based Therapy Developers
    • 6.3.1.1. Most Likely Partners
    • 6.3.1.2. Likely Partners
    • 6.3.1.3. Less Likely Partners
    • 6.3.1.4. Least Likely Partners
  • 6.3.2. Strategic Partner Analysis: Adenoviral Vector-based Therapy Developers
    • 6.3.2.1. Most Likely Partners
    • 6.3.2.2. Likely Partners
    • 6.3.2.3. Less Likely Partners
    • 6.3.2.4. Least Likely Partners
  • 6.3.3. Strategic Partner Analysis: Lentiviral Vector-based Therapy Developers
    • 6.3.3.1. Most Likely Partners
    • 6.3.3.2. Likely Partners
    • 6.3.3.3. Less Likely Partners
    • 6.3.3.4. Least Likely Partners
  • 6.3.4. Strategic Partner Analysis: Retroviral Vector-based Therapy Developers
    • 6.3.4.1. Most Likely Partners
    • 6.3.4.2. Likely Partners
    • 6.3.4.3. Less Likely Partners
    • 6.3.4.4. Least Likely Partners
  • 6.3.5. Strategic Partner Analysis: Other Viral Vector-based Therapy Developers
    • 6.3.5.1. Most Likely Partners
    • 6.3.5.2. Likely Partners
    • 6.3.5.3. Less Likely Partners
    • 6.3.5.4. Least Likely Partners
• 6.4. Potential Strategic Partners: Viral Vector Manufacturers
  • 6.4.1. Strategic Partner Analysis: AAV Vector Manufacturers
    • 6.4.1.1. Most Likely Partners
    • 6.4.1.2. Likely Partners
    • 6.4.1.3. Less Likely Partners
    • 6.4.1.4. Least Likely Partners
  • 6.4.2. Strategic Partner Analysis: Adenoviral Vector Manufacturers
    • 6.4.2.1. Most Likely Partners
    • 6.4.2.2. Likely Partners
    • 6.4.2.3. Less Likely Partners
    • 6.4.2.4. Least Likely Partners
  • 6.4.3. Strategic Partner Analysis: Lentiviral Vector Manufacturers
    • 6.4.3.1. Most Likely Partners
    • 6.4.3.2. Likely Partners
    • 6.4.3.3. Less Likely Partners
    • 6.4.3.4. Least Likely Partners
  • 6.4.4. Strategic Partner Analysis: Retroviral Vector Manufacturers
    • 6.4.4.1. Most Likely Partners
    • 6.4.4.2. Likely Partners
    • 6.4.4.3. Less Likely Partners
    • 6.4.4.4. Least Likely Partners
  • 6.4.5. Strategic Partner Analysis: Other Viral Vector Manufacturers
    • 6.4.5.1. Most Likely Partners
    • 6.4.5.2. Likely Partners
    • 6.4.5.3. Less Likely Partners
    • 6.4.5.4. Least Likely Partners

7. CLINICAL TRIAL ANALYSIS

• 7.1. Chapter Overview
• 7.2. Scope and Methodology
• 7.3. Viral Vector based Therapies: Clinical Trial Analysis
  • 7.3.1. Analysis by Trial Registration Year
  • 7.3.2. Analysis by Trial Phase
  • 7.3.3. Analysis by Trial Status
  • 7.3.4. Analysis by Type of Therapy
  • 7.3.5. Analysis by Therapeutic Area
  • 7.3.6. Analysis by Type of Sponsor / Collaborator
  • 7.3.7. Analysis by Geographical Location and Trial Status
  • 7.3.8. Most Active Players: Analysis by Number of Registered Trials
  • 7.3.9. Analysis by Patients Enrolled and Trial Phase
  • 7.3.10. Analysis by Patients Enrolled and Type of Therapy
  • 7.3.11. Analysis by Patients Enrolled and Therapeutic Area
  • 7.3.12. Analysis by Patients Enrolled, Trial Status and Geographical Location
• 7.4. AAV Vector based Therapies
  • 7.4.1. Analysis by Trial Registration Year
  • 7.4.2. Analysis by Trial Phase
  • 7.4.3. Analysis by Trial Status
  • 7.4.4. Analysis by Type of Therapy
  • 7.4.5. Analysis by Therapeutic Area
  • 7.4.6. Analysis by Type of Sponsor / Collaborator
  • 7.4.7. Analysis by Geographical Location and Trial Status
  • 7.4.8. Most Active Players: Analysis by Number of Registered Trials
  • 7.4.9. Analysis by Patients Enrolled and Trial Phase
  • 7.4.10. Analysis by Patients Enrolled and Type of Therapy
  • 7.4.11. Analysis by Patients Enrolled and Therapeutic Area
  • 7.4.12. Analysis by Patients Enrolled, Trial Status and Geographical Location
• 7.5. Adenoviral Vector based Therapies
  • 7.5.1. Analysis by Trial Registration Year
  • 7.5.2. Analysis by Trial Phase
  • 7.5.3. Analysis by Trial Status
  • 7.5.4. Analysis by Type of Therapy
  • 7.5.5. Analysis by Therapeutic Area
  • 7.5.6. Analysis by Type of Sponsor / Collaborator
  • 7.5.7. Analysis by Geographical Location and Trial Status
  • 7.5.8. Most Active Players: Analysis by Number of Registered Trials
  • 7.5.9. Analysis by Patients Enrolled and Trial Phase
  • 7.5.10. Analysis by Patients Enrolled and Type of Therapy
  • 7.5.11. Analysis by Patients Enrolled and Therapeutic Area
  • 7.5.12. Analysis by Patients Enrolled, Trial Status and Geographical Location
• 7.6. Lentiviral Vector based Therapies
  • 7.6.1. Analysis by Trial Registration Year
  • 7.6.2. Analysis by Trial Phase
  • 7.6.3. Analysis by Trial Status
  • 7.6.4. Analysis by Type of Therapy
  • 7.6.5. Analysis by Therapeutic Area
  • 7.6.6. Analysis by Type of Sponsor / Collaborator
  • 7.6.7. Analysis by Geographical Location and Trial Status
  • 7.6.8. Most Active Players: Analysis by Number of Registered Trials
  • 7.6.9. Analysis by Patients Enrolled and Trial Phase
  • 7.6.10. Analysis by Patients Enrolled and Type of Therapy
  • 7.6.11. Analysis by Patients Enrolled and Therapeutic Area
  • 7.6.12. Analysis by Patients Enrolled, Trial Status and Geographical Location
• 7.7. Retroviral Vector based Therapies
  • 7.7.1. Analysis by Trial Registration Year
  • 7.7.2. Analysis by Trial Phase
  • 7.7.3. Analysis by Trial Status
  • 7.7.4. Analysis by Type of Therapy
  • 7.7.5. Analysis by Therapeutic Area
  • 7.7.6. Analysis by Type of Sponsor / Collaborator
  • 7.7.7. Analysis by Geographical Location and Trial Status
  • 7.7.8. Most Active Players: Analysis by Number of Registered Trials
  • 7.7.9. Analysis by Patients Enrolled and Trial Phase
  • 7.7.10. Analysis by Patients Enrolled and Type of Therapy
  • 7.7.11. Analysis by Patients Enrolled and Therapeutic Area
  • 7.7.12. Analysis by Patients Enrolled, Trial Status and Geographical Location
• 7.8. Other Viral Vector based Therapies
  • 7.8.1. Analysis by Trial Registration Year
  • 7.8.2. Analysis by Trial Phase
  • 7.8.3. Analysis by Trial Status
  • 7.8.4. Analysis by Type of Therapy
  • 7.8.5. Analysis by Therapeutic Area
  • 7.8.6. Analysis by Type of Sponsor / Collaborator
  • 7.8.7. Analysis by Geographical Location and Trial Status
  • 7.8.8. Most Active Players: Analysis by Number of Registered Trials
  • 7.8.9. Analysis by Patients Enrolled and Trial Phase
  • 7.8.10. Analysis by Patients Enrolled and Type of Therapy
  • 7.8.11. Analysis by Patients Enrolled and Therapeutic Area
  • 7.8.12. Analysis by Patients Enrolled, Trial Status and Geographical Location

8. DEMAND ANALYSIS

• 8.1. Chapter Overview
• 8.2. Assumptions and Methodology
• 8.3. Global, Clinical Demand for Viral Vectors
  • 8.3.1. Analysis by Type of Vector
  • 8.3.2. Analysis by Type of Therapy
  • 8.3.3. Analysis by Therapeutic Area
  • 8.3.4. Analysis by Geographical Location
• 8.4. Global, Commercial Demand for Viral Vectors
  • 8.4.1. Analysis by Type of Vector
  • 8.4.2. Analysis by Type of Therapy
  • 8.4.3. Analysis by Therapeutic Area
  • 8.4.4. Analysis by Geographical Location

9. CASE STUDY: TANGENTIAL FLOW FILTRATION (TFF)

• 9.1. Chapter Overview
• 9.2. Role of TFF in Viral Vector Purification
  • 9.2.1. Advantages of TFF
  • 9.2.2. Disadvantages of TFF
• 9.3. TFF-related Product Suppliers

10. CASE STUDY: VIRAL VECTOR MANUFACTURERS

• 10.1. Chapter Overview
• 10.2. Commercial Scale Viral Vector Manufacturers
  • 10.2.1. Analysis by Year of Establishment
  • 10.2.2. Analysis by Company Size
  • 10.2.3. Analysis by Type of Viral Vector
  • 10.2.4. Analysis by Purpose of Production
  • 10.2.5. Analysis by Geographical Location

11. MARKET SIZING AND OPPORTUNITY ANALYSIS

• 11.1. Chapter Overview
• 11.2. Forecast Methodology and Key Assumptions
• 11.3. Overall Viral Vector Purification Products Market, Till 2035
  • 11.3.1. Viral Vector Purification Products Market: Distribution by Type of Viral Vector, Till 2035
  • 11.3.2. Viral Vector Purification Products Market: Distribution by Type of Purification Technique, Till 2035
  • 11.3.3. Viral Vector Purification Products Market: Distribution by Type of Therapy, Till 2035
  • 11.3.4. Viral Vector Purification Products Market: Distribution by Therapeutic Area, Till 2035
  • 11.3.5. Viral Vector Purification Products Market: Distribution by Scale of Operation, Till 2035
  • 11.3.6. Viral Vector Purification Products Market: Distribution by Geographical Location, Till 2035
• 11.4. Viral Vector Purification Products Market for AAV Vectors, Till 2035
  • 11.4.1. AAV Vector Purification Products Market: Distribution by Type of Purification Technique, Till 2035
  • 11.4.2. AAV Vector Purification Products Market: Distribution by Type of Therapy, Till 2035
  • 11.4.3. AAV Vector Purification Products Market: Distribution by Therapeutic Area, Till 2035
  • 11.4.4. AAV Vector Purification Products Market: Distribution by Scale of Operation, Till 2035
  • 11.4.5. AAV Vector Purification Products Market: Distribution by Geographical Location, Till 2035
• 11.5. Viral Vector Purification Products Market for Adenoviral Vectors, Till 2035
  • 11.5.1. Adenoviral Vector Purification Products Market: Distribution by Type of Purification Technique, Till 2035
  • 11.5.2. Adenoviral Vector Purification Products Market: Distribution by Type of Therapy, Till 2035
  • 11.5.3. Adenoviral Vector Purification Products Market: Distribution by Therapeutic Area, Till 2035
  • 11.5.4. Adenoviral Vector Purification Products Market: Distribution by Scale of Operation, Till 2035
  • 11.5.5. Adenoviral Vector Purification Products Market: Distribution by Geographical Location, Till 2035
• 11.6. Viral Vector Purification Products Market for Lentiviral Vectors, Till 2035
  • 11.6.1. Lentiviral Vector Purification Products Market: Distribution by Type of Purification Technique, Till 2035
  • 11.6.2. Lentiviral Vector Purification Products Market: Distribution by Type of Therapy, Till 2035
  • 11.6.3. Lentiviral Vector Purification Products Market: Distribution by Therapeutic Area, Till 2035
  • 11.6.4. Lentiviral Vector Purification Products Market: Distribution by Scale of Operation, Till 2035
  • 11.6.5. Lentiviral Vector Purification Products Market: Distribution by Geographical Location, Till 2035
• 11.7. Viral Vector Purification Products Market for Retroviral Vectors, Till 2035
  • 11.7.1. Retroviral Vector Purification Products Market: Distribution by Type of Purification Technique, Till 2035
  • 11.7.2. Retroviral Vector Purification Products Market: Distribution by Type of Therapy, Till 2035
  • 11.7.3. Retroviral Vector Purification Products Market: Distribution by Therapeutic Area, Till 2035
  • 11.7.4. Retroviral Vector Purification Products Market: Distribution by Scale of Operation, Till 2035
  • 11.7.5. Retroviral Vector Purification Products Market: Distribution by Geographical Location, Till 2035
• 11.8. Viral Vector Purification Products Market for Other Viral Vectors, Till 2035
  • 11.8.1. Other Viral Vector Purification Products Market: Distribution by Type of Purification Technique, Till 2035
  • 11.8.2. Other Viral Vector Purification Products Market: Distribution by Type of Therapy, Till 2035
  • 11.8.3. Other Viral Vector Purification Products Market: Distribution by Therapeutic Area, Till 2035
  • 11.8.4. Other Viral Vector Purification Products Market: Distribution by Scale of Operation, Till 2035
  • 11.8.5. Other Viral Vector Purification Products Market: Distribution by Geographical Location, Till 2035

12. CONCLUDING REMARKS

13. EXECUTIVE INSIGHTS

• 13.1. Chapter Overview
• 13.2. Company A
  • 13.2.1. Company Snapshot
  • 13.2.2. Interview Transcript: Chief Executive Officer
• 13.3. Company B
  • 13.3.1. Company Snapshot
  • 13.3.2. Interview Transcript: Chief Commercial Officer
• 13.4. Company C
  • 13.4.1. Company Snapshot
  • 13.4.2. Interview Transcript: Chief Scientific Officer

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS